Dr. Eve T. Rodler, MD

Dr. Rodler practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Rodler's NPI, 1811069115, was assigned on November 14, 2006. Dr. Rodler graduated from George Washington University School of Medicine in 1997. Dr. Rodler holds California license A68252.

Dr. Rodler's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Rodler's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Rodler to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rodler practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rodler's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Rodler is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Rodler's licenses on file in 4 states: California, Washington, New Jersey and Illinois.

Dmand AI lists breast cancer among the conditions Dr. Rodler treats.

CMS data shows 152 Medicare services from Dr. Rodler across 3 procedure codes in 2024, for 49 Medicare patients. Medicare paid $6,569 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 49 Medicare patients who saw Dr. Rodler in 2024. The largest group is 65 to 74, with 24 patients. 75% of them have cancer, and 73% have high cholesterol. Their average risk score is 1.20, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Rodler's median patient age at 65, with 91% women.

In 2024, Dr. Rodler wrote 363 Medicare Part D claims for 53 patients. 83% of them were for generic drugs. CMS names the drug for 254 of them, across 7 drugs with 11 or more claims each, at $456,998 in total drug cost. In 2023, CMS named 235 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Rodler for performance year 2024, reported as part of a group. Dr. Rodler accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rodler as offering telehealth.

Dmand AI links 30 papers to Dr. Rodler, published from 2011 to 2024. 2012 was the busiest year, with 6. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy and Sarcoma. Dr. Rodler has published most often in Cancer. Dr. Rodler's most frequent co-authors are Elizabeth Trice Loggers, MD, PhD, Julie R. Gralow, MD and Margaret Block, MD.

Dmand AI links Dr. Rodler to 3 clinical trials. Conditions studied include Sarcoma, Triple Negative Breast Neoplasms and Brain Neoplasms.

Dr. Rodler graduated from George Washington University School of Medicine in 1997.

Dr. Rodler is in network with 9 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.